BAX logo

BAXTER INTERNATIONAL INC

BAXNYSE
πŸ† #575 by market capEarnings Oct 28US Equity
$27.61β–Ό $0.17 (βˆ’0.63%)
Market closed Β· at close
1hβ€”
24hβ–Ό 0.6%
7dβ–² 1.0%
14dβ–² 11.5%
30dβ–² 22.2%
1yβ–² 15.2%
🏦Market Cap
$14.26B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+5.4%
Slowing
πŸ“ŠGross Margin
30.7%
Moderate
πŸ’΅FCF Margin
7.1%
Moderate
βš–οΈP/S Ratio
1.3x
Cheap
Otter Score
55
Weak

Trading Snapshot

Day Range
$27.20 – $28.03
52-Week Range
$15.73 – $30.00
Volume
$2.70B
Avg Volume
$2.00B
Shares Outstanding
516.5M
Next Earnings
Oct 17, 2026

Fundamentals Snapshot

Annual Revenue
$11.24B
Last Q Revenue
$2.96B
P/E Ratio
β€”
P/S Ratio
1.3x
EPS (TTM)
$-2.07
Dividend Yield
1.28%

Why Investors Own BAX

  • βœ“High-growth profile β€” revenue up +6.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 70% gross margin and 28% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$11.24Bβ–² +11.1% YoY
Gross Margin (TTM)
70.1%β–² +2.8% YoY
Operating Income (TTM)
$1.43Bβ–² +11.1% YoY
Free Cash Flow (TTM)
$3.16Bβ–² +11.1% YoY

About BAXTER INTERNATIONAL INC

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
55/100

Analyst Ratings

β“˜
Consensus
Hold
20 analysts
Strong Buy1
Buy4
Hold14
Sell1
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

YahooΒ·4d ago

Does Cardinal Health’s New CAO and Recalls Reveal Shifts in Its Risk Profile and Earnings Quality (CAH)?

In early August 2026, Cardinal Health announced that Anita Zielinski will become Chief Accounting Officer in November, following her interim CFO and senior accounting roles at Baxter and long tenure at Sysco and Ernst & Young, while the company also faced ongoing Class II recalls of subpotent levothyroxine tablets distributed nationwide in the US. This combination of leadership change in Cardinal Health’s finance function and routine but nationwide product recalls comes as analysts are...

πŸ›°οΈ
BenzingaΒ·7d ago

Baxter International Says Anita Zielinski To Resign As Interim CFO, Effective September 15, 2026

-SEC Filing

🌌
FintelΒ·7d ago

Baxter International (BAX) Price Target Increased by 25.96% to 27.05

YahooΒ·7d ago

Baxter Announces Cash Tender Offers

DEERFIELD, Ill., August 04, 2026--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has commenced cash tender offers (each, an "Offer" and collectively, the "Offers") for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the "Notes"), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million.

ChartMillΒ·8d ago

Exploring the top movers within the S&P500 index during today's session.

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.

ChartMillΒ·8d ago

Explore the top gainers and losers within the S&P500 index in today's session.

Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.